Physician profile
Sharon Mitchell
NPI 1417145913
$706.52
in general payments reported to CMS, 2019-2025
14 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $41.93 · 2021: $188 · 2022: $77.66 · 2024: $56.44 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.18 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $238.69 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.44 | 2022-2025 | |
| Abbvie INC. | $62.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $60.07 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $59.05 | 2019 | |
| Medtronic, INC. | $34.58 | 2025 | Minimed 780g |
| Novo Nordisk INC | $29.62 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $23.44 | 2019 | |
| Esperion Therapeutics, INC. | $17.04 | 2022 | |
| Merck Sharp & Dohme LLC | $16.61 | 2021 | |
| Dexcom, INC. | $16.43 | 2025 | Dexcom G6 Transmitter |
| Medicure Pharma INC. | $14.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.25 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.